|Active substance||Bendamustine (C16H21Cl2N3O2)|
|US Brand||Treanda, Treakisym, Ribomustin, Levact.|
|Manufacturing by India||Natco Pharma|
|Form release||Liophilized powder for injections|
|Estimated shipping time||7 – 18 days (Depending from the Country)|
|Availability, Prices & Order||through request form|
Bendamustine, is a chemotherapy medication used in the treatment of chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma. It is given by injection into a vein.
Bendamustine was approved for medical use in the United States in 2008. It is on the World Health Organization’s List of Essential Medicines, the most effective and safe medicines needed in a health system.
Bendamustine is a white, water-soluble microcrystalline powder with amphoteric properties. It acts as an alkylating agent causing intra-strand and inter-strand cross-links between DNA bases.
After intravenous infusion it is extensively metabolised in the liver by cytochrome p450. More than 95% of the drug is bound to protein – primarily albumin. Only free bendamustine is active. Elimination is biphasic with a half-life of 6–10 minutes and a terminal half-life of approximately 30 minutes. It is eliminated primarily through the kidneys.
Usual Adult Dose for Chronic Lymphocytic Leukemia
100 mg/m2 IV on Days 1 and 2 of a 28-day cycle
Duration of Therapy: Up to 6 cycles
-Administer this drug via IV infusion over 10 or 30 minutes; consult the manufacturer product information for specific IV infusion time period.
-Efficacy of this drug relative to first-line therapies other than chlorambucil has not been established.
Use: Treatment of chronic lymphocytic leukemia
Usual Adult Dose for non-Hodgkin’s Lymphoma
120 mg/m2 IV on Days 1 and 2 of a 21-day cycle
Duration of Therapy: Up to 8 cycles
Comments: Administer this drug via IV infusion over 10 or 60 minutes; consult the manufacturer product information for specific IV infusion time period.
Use: Treatment of indolent B-Cell non-Hodgkin lymphoma that has progressed during or within 6 months of treatment with rituximab or a rituximab-containing regimen.
Common side effects include low blood cell counts, fever, nausea, diarrhea, loss of appetite, cough, and rash. Other severe side effects include allergic reactions and increased risk of infection. Use in pregnancy is known to harm the baby. Bendamustine is in the alkylating agents family of medication. It works by interfering with the function of DNA and RNA.